Geza L.
- Country
- Hungary
- Department
- N/A
Research Overview
- Efficacy and Safety of Early In-Hospital Inclisiran Initiation in Patients with Acute Coronary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study
- J2O-MC-EKBC: KRAKEN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Once-Daily LY3473329 in Adults with Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
- Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 868 of 1509 partner sites.
Specializations
Heart Failure Research
The investigator specializes in clinical research focused on heart failure treatment, with particular emphasis on both reduced and preserved ejection fraction conditions. Their work encompasses studies of novel therapeutic agents for acute and chronic heart failure management.
- Heart Failure with Reduced Ejection Fraction (HFrEF)
- Heart Failure with Preserved Ejection Fraction (HFpEF)
- Acute Heart Failure Interventions
Cardiovascular Disease Management
This investigator conducts research in cardiovascular therapeutics, focusing on innovative treatments for various cardiac conditions including myocardial infarction and atrial fibrillation.
- Acute Coronary Syndrome
- ST-Elevation Myocardial Infarction
- Atrial Fibrillation
- Hypertrophic Cardiomyopathy
Metabolic Disorders
The investigator's research extends to lipid disorders and metabolic conditions affecting cardiovascular health, including studies on treatments for various forms of hypertriglyceridemia.
- Severe Hypertriglyceridemia
- Lipoprotein Disorders
- Atherosclerotic Cardiovascular Disease
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.